Author pages are created from data sourced from our academic publisher partnerships and public sources.
The risk of cancer in users of statins.
- M. R. Graaf, A. Beiderbeck, A. C. Egberts, D. Richel, H. Guchelaar
- Medicine, Mathematics
- Journal of clinical oncology : official journal…
- 15 June 2004
PURPOSE Several preclinical studies suggested a role for 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) in the treatment of cancer. The objective of this study was to compare… Expand
Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.
- J. Wessels, J. D. de Vries-Bouwstra, +9 authors H. Guchelaar
- Arthritis and rheumatism
- 1 April 2006
OBJECTIVE To determine associations of methotrexate (MTX) efficacy and toxicity with single-nucleotide polymorphisms (SNPs) in genes coding for folate pathway enzymes in patients with early… Expand
Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
- A. V. D. van der Veldt, K. Eechoute, +7 authors J. Wessels
- Clinical Cancer Research
- 19 November 2010
Purpose: The objective of this study was to identify genetic polymorphisms related to the pharmacokinetics and pharmacodynamics of sunitinib that are associated with a prolonged progression-free… Expand
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
- M. R. Graaf, D. Richel, C. J. V. van Noorden, H. Guchelaar
- Cancer treatment reviews
- 1 November 2004
Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors - HMG-CoA reductase inhibitors) have been approved for the treatment of lipid disorders. Recently, in vivo studies with… Expand
A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.
OBJECTIVE To develop a clinical pharmacogenetic model to predict the efficacy of methotrexate (MTX) in rheumatoid arthritis (RA). METHODS Two hundred five patients with newly diagnosed RA and… Expand
Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
Purpose: To explore the effect of dihydropyrimidine dehydrogenase (DPD) single nucleotide polymorphisms (SNP) and haplotypes on outcome of capecitabine. Experimental Design: Germline DNA was… Expand
Glutathione S-transferase Polymorphisms Are Not Associated With Population Pharmacokinetic Parameters of Busulfan in Pediatric Patients
- J. Zwaveling, R. R. Press, +5 authors H. Guchelaar
- Biology, Medicine
- Therapeutic drug monitoring
- 1 July 2008
High busulfan exposure is associated with increased toxicity, for example veno-occlusive disease, whereas low exposure results in less efficacy such as lower engraftment rates. Despite adjusting dose… Expand
Cardiotoxicity of cytotoxic drugs.
- K. Schimmel, D. Richel, R. V. D. van den Brink, H. Guchelaar
- Cancer treatment reviews
- 1 April 2004
Cardiotoxicity is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. The mechanism of anthracycline induced cardiotoxicity… Expand
Translating Pharmacogenomics: Challenges on the Road to the Clinic
Pharmacogenomics is one of the first clinical applications of the postgenomic era. It promises personalized medicine rather than the established “one size fits all” approach to drugs and dosages. The… Expand
A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
Pharmacogenetics is the search for heritable genetic polymorphisms that influence responses to drug therapy. The most important application of pharmacogenetics is to guide choosing agents with the… Expand